Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraził świadomą zgodę na uczestnictwo w badaniu
- •Rozpoznany zaawansowany nowotwór stały z mutacją KRAS p.G12C, niepoddający się standardowemu leczeniu lub pacjent go nie toleruje
- •Spodziewana długość życia co najmniej 3 miesiące
- •Pacjent ma co najmniej jednego guza widocznego na badaniach (wg kryteriów RECIST v1.1)
- •Ogólny stan zdrowia pacjenta pozwala na leczenie (stan wydolności 0-1 wg ECOG)
- •Funkcje narządów wewnętrznych w normie (wyniki badań laboratoryjnych)
- •Pacjent może połykać leki bez problemów żołądkowo-jelitowych, które utrudniałyby wchłanianie
✗ Disqualifies
- •Historia innego nowotworu w ciągu ostatnich 3 lat (z wyjątkami dla raków niewymagających leczenia)
- •Ciężka alergia na badane leki lub ich składniki
- •Poważne choroby autoimmuniczne w ciągu ostatnich 6 miesięcy lub potrzeba długotrwałego leczenia sterydami
- •Wcześniejsze ciężkie komplikacje po immunoterapii przeciwnowotworowej
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (27)
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, China
Pecking Union Medical College Hospital
Beijing, China
Cancer Hospital Chinese Academy Of Medical Sciences
Beijing, China
Beijing Tiantan Hospital, Captal Medical University
Beijing, China
Beijing Cancer Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Beijing Chest Hospital, Capital Medical University
Beijing, China
Fujian cancer Hospital
Fuzhou, China
The First Affiliated Hospital Xiamen University
Xiamen, China
The first Affiliated Hospital, Sun Yat-sen University
Guangzhou, China
Zhujiang Hospital of Southem Medical University
Guangzhou, China
Cancer Hospital Chinese Academy Of medical Sciences Shenzhen Center
Shenzhen, China
Harbin Medical University Cancer Hospital-Mammary gland of internal
Harbin, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hosipital Of Zhengzhou University
Zhengzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Tongji Hospital Tongji Medical College of Hust
Wuhan, China
Renmin Hospital Of Wuhan University
Wuhan, China
Xiangya Hospital Central South Univesity
Changsha, China
Hunan Cancer Hospital
Changsha, China
The First Hospital Of China Medical University
Shenyang, China
The Affilated Hospital of Inner Mongolia Medical University
Hohhot, China
Qilu Hospital of Shandong University
Jinan, China
Shandong Cancer Hospital
Jinan, China
LinYi Cancer Hospital
Linyi, China
Fudan University Shanghai Cancer Center
Shanghai, China
The Second Affiliated Hospital Zhejiang School of Medicine
Hangzhou, China
Trial contact
Shanghai Allist Pharmaceuticals Co., Ltd Shanghai Allist Pharmaceuticals Co., Ltd
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.